Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...
Oklahoma Attorney General Gentner Drummond Office on Wednesday confirmed action is in order with the Food and Drug ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...
Technology is transforming every aspect of our lives, and weight loss is no exception. From AI-driven meal plans to wearable fitness trackers, the future of weight loss is becoming more personalized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback